Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders

Front Immunol. 2021 Mar 25:12:569287. doi: 10.3389/fimmu.2021.569287. eCollection 2021.

Abstract

Bullous pemphigoid (BP) is a prototypic autoimmune disorder of the elderly, characterized by serum IgG autoantibodies, namely anti-BP180 and anti-BP230, directed against components of the basal membrane zone that lead to sub-epidermal loss of adhesion. Pruritus may be indicative of a pre-clinical stage of BP, since a subset of these patients shows serum IgG autoantibodies against BP230 and/or BP180 while chronic pruritus is increasingly common in the elderly population and is associated with a variety of dermatoses. Clinical and experimental evidence further suggests that pruritus of the elderly may be linked to autoimmunity with loss of self-tolerance against cutaneous autoantigens. Thus, the objective of this study was to determine autoreactive T cell responses against BP180 in elderly patients in comparison to patients with BP. A total of 22 elderly patients with pruritic disorders, 34 patients with bullous or non-bullous BP and 34 age-matched healthy controls were included in this study. The level of anti-BP180 and anti-BP230 IgG serum autoantibodies, Bullous Pemphigoid Disease Area Index (BPDAI), and pruritus severity were assessed for all patients and controls. For characterization of the autoreactive T cell response, peripheral blood mononuclear cells were stimulated ex vivo with recombinant BP180 proteins (NH2- and COOH-terminal domains) and the frequencies of BP180-specific T cells producing interferon-γ, interleukin (IL)-5 or IL-17 were subsequently determined by ELISpot assay. Patients with BP showed a mixed Th1/Th2 response against BP180 while autoreactive Th1 cells were identified in a minor subset of elderly patients with pruritic disorders. Furthermore, our T cell characterization revealed that therapeutic application of topical clobetasol propionate ointment in BP patients significantly reduced peripheral blood BP180-specific T cells, along with clinically improved symptoms, strongly suggesting a systemic immunosuppressive effect of this treatment.

Keywords: BP180; ELISpot assay; T cells; autoimmunity; pemphigoid; pruritus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Autoantibodies / blood
  • Autoantibodies / immunology
  • Autoantigens / immunology
  • Autoimmunity / immunology*
  • Clobetasol / therapeutic use
  • Cohort Studies
  • Collagen Type XVII
  • Cytokines / immunology
  • Cytokines / metabolism
  • Dystonin / immunology
  • Enzyme-Linked Immunospot Assay
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Non-Fibrillar Collagens / immunology
  • Ointments
  • Pemphigoid, Bullous / complications
  • Pemphigoid, Bullous / drug therapy
  • Pemphigoid, Bullous / immunology*
  • Pruritus / complications
  • Pruritus / immunology*
  • T-Lymphocytes, Helper-Inducer / drug effects
  • T-Lymphocytes, Helper-Inducer / immunology*
  • T-Lymphocytes, Helper-Inducer / metabolism
  • Th17 Cells / drug effects
  • Th17 Cells / immunology
  • Th17 Cells / metabolism

Substances

  • Autoantibodies
  • Autoantigens
  • Cytokines
  • DST protein, human
  • Dystonin
  • Glucocorticoids
  • Immunoglobulin G
  • Non-Fibrillar Collagens
  • Ointments
  • Clobetasol